Last reviewed · How we verify
Progesterone Vaginal Gel [Crinone]
Progesterone binds to progesterone receptors in the uterus to support the luteal phase and maintain pregnancy.
Progesterone binds to progesterone receptors in the uterus to support the luteal phase and maintain pregnancy. Used for Luteal phase support in assisted reproductive technology (ART) cycles, Infertility due to inadequate luteal phase.
At a glance
| Generic name | Progesterone Vaginal Gel [Crinone] |
|---|---|
| Also known as | Crinone %8 vaginal progesterone gel |
| Sponsor | Memorial Sisli Hospital, Istanbul |
| Drug class | Progestin; Progesterone receptor agonist |
| Target | Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive/Fertility |
| Phase | FDA-approved |
Mechanism of action
Progesterone is a naturally occurring steroid hormone that acts as a ligand for intracellular progesterone receptors, primarily in the endometrium. This binding promotes endometrial secretion, suppresses uterine contractions, and maintains the uterine environment necessary for embryo implantation and early pregnancy maintenance. The vaginal gel formulation (Crinone) delivers progesterone directly to the reproductive tract for local and systemic absorption.
Approved indications
- Luteal phase support in assisted reproductive technology (ART) cycles
- Infertility due to inadequate luteal phase
Common side effects
- Vaginal irritation or discharge
- Headache
- Breast tenderness
- Abdominal pain or cramping
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: